Browse by Industry
Filter News
Found 86,882 articles
-
Novartis acquired Vedere Bio in a deal totaling up to $280 million. The takeout broadens Novartis’ footprint in gene and cell therapy, with Vedere Bio’s gene therapy platforms for ophthalmic disorders.
-
THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid tumors.
-
Arcus will pair its investigational anti-TIGIT antibody domvanalimab (AB154) with AstraZeneca’s Imfinzi (durvalumab), a checkpoint inhibitor, in a Phase III study with patients who have unresectable Stage III NSCLC.
-
Texas is “Going Big” in Biopharma
10/29/2020
Texas wants to get the word out: It’s not just for oil and pipelines anymore. The Lone Star State is a rapidly emerging biopharma hub, with more than just a lone focus on oncology. -
BioSpace Global Roundup, Oct. 29
10/29/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
AstraZeneca and Daiichi Sankyo’s Enhertu received supplemental Biologics License Application acceptance and U.S. priority review for the treatment of HER2-positive metastatic gastric – or gastroesophageal junction cancer.
-
Nanox Signs With Ambra Health to Enable Image Access and Transfer with U.S. Hospitals and Medical imaging Providers
10/29/2020
NANO-X IMAGING LTD ( https://www.nanox.vision/ ) (“Nanox” or the “Company”), an innovative medical imaging company, announced today it has signed an agreement with Ambra Health , a leading medical data and image management cloud software company, to facilitate the transfer of medical images between U.S. hospitals and medical imaging providers. Per the terms of the agreement, Ambra will serve as the enterprise image exchange solution
-
Synedgen Receives Supplemental NEI Funding to Identify Lead Development Candidate for Ocular Mustard Gas Injury Program
10/29/2020
Synedgen, a biotechnology company using glycopolymer chemistry to develop drugs that enhance and control signaling in the innate immune system, today announced supplemental funding from the National Eye Institute (NEI) of the NIH to identify a lead molecule from the company’s ocular mustard gas injury program to move into animal studies.
-
QurAlis Announces Appointment of New Chief Medical Officer and Formation of Clinical Advisory Board
10/29/2020
QurAlis Corporation , a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the appointment of Angela Genge, MD, FRCP(C), eMBA to the position of Chief Medical Officer (CMO). Dr. Genge is the Executive Director of the Mon
-
enGene Receives Funding Through Cystic Fibrosis Foundation's Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis
10/29/2020
enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today an award from the Cystic Fibrosis Foundation for the discovery of genetic medicines to treat patients with cystic fibrosis (CF).
-
Insignis Therapeutics and HLK Pharmacin Receive FDA IND Clearance to Initiate a Phase 1 Trial With IN-001 for Oral Anaphylaxis Treatment
10/29/2020
Insignis Therapeutics (“Insignis”), a biotech company focused on developing innovative therapeutics for anaphylaxis treatment and HLK Pharmacin, a global drug development company, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application
-
Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19
10/29/2020
Initial information sharing agreement signed to further research into the anti-viral potential of WP1122
-
Tricida Provides Update on FDA Interactions
10/29/2020
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it held an End-of-Review conference as a Type A meeting with the Division of Cardiology and Nephrolo
-
Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a Analysis
10/29/2020
Company Will Report Data from Phase 2a Sensorineural Hearing Loss (SNHL) Study in Late Q1 2021 First Patient Dosed in Phase 1b Study of Age-Related Hearing Loss; Additional Phase 1b Study for Severe SNHL Patients to Start This Quarter
-
AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑01, an Investigational Gene Therapy for Fabry Disease
10/29/2020
AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-01, the company’s investigational gene therapy for the treatment of Fabry disease. AVR-RD-01, an ex-vivo, lentiviral gene therapy, consists of the patient’s own hematopoietic stem ce
-
Boston Scientific Initiates Trial to Evaluate WATCHMAN FLX™ Left Atrial Appendage Closure Device as First-Line Treatment for People at Risk of Stroke
10/29/2020
Trial to study next-generation device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation
-
Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
10/29/2020
Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, reported financial results for the third quarter ended September 30, 2020, and provided a business update on recent corporate and clinical developments.
-
Mallinckrodt Announces Data at Kidney Week 2020 Reimagined that Showed A Potential for Reduced Need for Renal Replacement (RRT) Therapy for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Treated with Terlipressin
10/29/2020
Post-hoc, pooled analyses of three Phase 3 trials found HRS-1 patients treated with terlipressin was associated with less RRT up to Day 90 versus placebo
-
IDEXX Laboratories Announces Third Quarter 2020 Results
10/29/2020
IDEXX Laboratories, Inc., a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, announced third quarter results, as well as business and market condition updates related to the 2019 novel coronavirus pandemic.
-
Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan
10/29/2020
MHLW and Takeda will import and distribute mRNA-1273 in Japan starting in the first half of 2021